Retinoic Acid Homeostasis in Neuropsychiatric Diseases
NCT02439099 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2021-08-09
Summary
It is hypothesized, that local retinoic acid (RA) homeostasis is functionally involved in the pathophysiology of depression. In a cross-sectional (and partly longitudinal) analysis, serum RA status will be assessed in healthy controls and subjects with Major Depression, Alzheimer's disease, alcoholism and in subjects with schizophrenia.
Conditions
- Major Depression
- Alzheimer's Disease
- Alcoholism
- Schizophrenia
Sponsors & Collaborators
-
Charite University, Berlin, Germany
lead OTHER
Principal Investigators
-
Isabella Heuser, MD, PhD · Chair: Department of Psychiatry, Charité, CBF
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-03-31
- Primary Completion
- 2022-12-31
- Completion
- 2022-12-31
Countries
- Germany
Study Locations
More Related Trials
-
Study on the Influence of Electroconvulsive Therapy (ECT) on Homocysteine Levels
NCT00370058 ·Status: COMPLETED ·Phase: PHASE4
-
Somatosensory Processing in Depression
NCT00386893 ·Status: WITHDRAWN ·Phase: PHASE4
-
Treatment Outcome in Major Depressive Disorder
NCT02869035 ·Status: COMPLETED ·Phase: PHASE1
-
Mechanisms of Antidepressant Non-Response in Late-Life Depression
NCT01931202 ·Status: COMPLETED ·Phase: NA
-
Repeated Neurocognitive Measurements in Depressed Patients
NCT04916548 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
NCT00707863 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's Dementia
NCT00229333 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
NCT01564862 ·Status: COMPLETED ·Phase: PHASE2
-
Escitalopram for the Treatment of Depression in Alzheimer's Disease
NCT01841125 ·Status: COMPLETED ·Phase: PHASE4
-
Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response
NCT01251471 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
NCT01422213 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
NCT01395147 ·Status: COMPLETED ·Phase: PHASE3
-
Cognitive Dysfunction in MDD Patients
NCT03187093 ·Status: UNKNOWN ·Phase: PHASE4
-
Brain Effects of Escitalopram and Citalopram Using fMRI
NCT00825825 ·Status: COMPLETED ·Phase: PHASE4
-
Long-term Follow-up of Depressive Disorders in Psychiatric Care
NCT07078227 ·Status: RECRUITING
-
Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder
NCT06532604 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
NCT01876823 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression
NCT00386841 ·Status: COMPLETED ·Phase: PHASE4
-
Aβ Dynamics in LLMD
NCT05004987 ·Status: RECRUITING ·Phase: PHASE4
-
Effects of Altitude-like Cognition Training on Neuroplasticity and Cognitive Functions
NCT06121206 ·Status: COMPLETED ·Phase: NA
-
Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder
NCT00442481 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders
NCT03315897 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
NCT01152996 ·Status: COMPLETED ·Phase: PHASE3
-
Emotional and Cognitive Control in Late-Onset Depression
NCT01728194 ·Status: COMPLETED ·Phase: PHASE4
-
Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression
NCT02132286 ·Status: COMPLETED ·Phase: PHASE4